Predictive value of pretreatment circulating inflammatory response markers in the neoadjuvant treatment of breast cancer: meta-analysis
British Journal of Surgery · 2024
DOI: 10.1093/bjs/znae132 ↗Kurz gefasst
Metaanalyse in der Zeitschrift British Journal of Surgery, 2024. Verfasst von Gavin P Dowling und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Royal College of Surgeons in Ireland (RCSI) University of Medicine and Health Sciences, Dublin, Ireland. Hauptthemen laut MEDLINE: Breast Neoplasms, Neoadjuvant Therapy. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 73 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: RCSI-Bon Secours Hospital Dublin.
Abstract (Originalsprache)
Background
Systemic inflammatory response markers have been found to have a prognostic role in several cancers, but their value in predicting the response to neoadjuvant chemotherapy in breast cancer is uncertain. A systematic review and meta-analysis of the literature was carried out to investigate this.
Methods
A systematic search of electronic databases was conducted to identify studies that explored the predictive value of circulating systemic inflammatory response markers in patients with breast cancer before commencing neoadjuvant therapy. A meta-analysis was undertaken for each inflammatory marker where three or more studies reported pCR rates in relation to the inflammatory marker. Outcome data are reported as ORs and 95% confidence intervals.
Results
A total of 49 studies were included, of which 42 were suitable for meta-analysis. A lower pretreatment neutrophil-to-lymphocyte ratio was associated with an increased pCR rate (pooled OR 1.66 (95% c.i. 1.32 to 2.09); P < 0.001). A lower white cell count (OR 1.96 (95% c.i. 1.29 to 2.97); P = 0.002) and a lower monocyte count (OR 3.20 (95% c.i. 1.71 to 5.97); P < 0.001) were also associated with a pCR. A higher lymphocyte count was associated with an increased pCR rate (OR 0.44 (95% c.i. 0.30 to 0.64); P < 0.001).
Conclusion
The present study found the pretreatment neutrophil-to-lymphocyte ratio, white cell count, lymphocyte count, and monocyte count of value in the prediction of a pCR in the neoadjuvant treatment of breast cancer. Further research is required to determine their value in specific breast cancer subtypes and to establish optimal cut-off values, before their adoption in clinical practice.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Surgery, Royal College of Surgeons in Ireland (RCSI) University of Medicine and Health Sciences, Dublin, Ireland.
- Medical Oncology Lab, Department of Molecular Medicine, Royal College of Surgeons in Ireland (RCSI) University of Medicine and Health Sciences, Dublin, Ireland.
- Department of Surgery, Beaumont Hospital, Dublin, Ireland.
ORCID-Profile: Gavin P Dowling, Sandra Hembrecht
Förderung
- RCSI-Bon Secours Hospital Dublin
Zitieren
APA
Dowling, G. P., Daly, G. R., Hegarty, A., Hembrecht, S., Bracken, A., Toomey, S., Hennessy, B. T., & Hill, A. D. K. (2024). Predictive value of pretreatment circulating inflammatory response markers in the neoadjuvant treatment of breast cancer: meta-analysis. British Journal of Surgery. https://doi.org/10.1093/bjs/znae132
Vancouver
Dowling GP, Daly GR, Hegarty A, Hembrecht S, Bracken A, Toomey S, et al. Predictive value of pretreatment circulating inflammatory response markers in the neoadjuvant treatment of breast cancer: meta-analysis. British Journal of Surgery. 2024. doi:10.1093/bjs/znae132
BibTeX
@article{Dowling2024,
author = {Dowling, Gavin P and Daly, Gordon R and Hegarty, Aisling and Hembrecht, Sandra and Bracken, Aisling and Toomey, Sinead and Hennessy, Bryan T and Hill, Arnold D K},
title = {Predictive value of pretreatment circulating inflammatory response markers in the neoadjuvant treatment of breast cancer: meta-analysis},
journal = {British Journal of Surgery},
year = {2024},
doi = {10.1093/bjs/znae132}
}
EUVIMED